Search global stocks & ETFs...Ctrl K

Learn Mode

VTRS - Viatris Inc

51

$15.95

$0.43 (2.771%)

At market close

$15.83

-$0.13 (-0.784%)

After Hours 5/6/26, 9:22 PM

Score

2.57/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

VTRS

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$18.07B

Industry

Pharmaceuticals

EPS (TTM)

-$3.04

P/E (TTM)

0.00

Div & Yield

$0.48 (3.01%)

FCF Payout Ratio

29.38%

P/S (TTM)

1.26

P/B

1.23

Diluted Shares

1.15B

Ex-Dividend

2026-03-09

Next Earnings

05-07

Forward P/E

6.26

Payout Ratio

0.00%

P/FCF (TTM)

9.76

FCF Yield

10.24%

Earnings Yield

-19.45%

52 Week Range

Score Card

Explore Scores Tab

2.57

Bad

Viatris Inc has seen its revenue decline by -2.98% over the past year, which means the company is losing sales/customers. However, it has seen its diluted average shares outstanding decrease by -3.4% over the past year, which suggests the company is buying back shares.

Valuation Model

Key Score

5.00

Very Good

Management

4.00

Good

Growth

3.00

Average

Profitability

3.00

Average

Fin. Health

5.00

Very Good

Dividends

3.00

Average

Analyst

5.00

Very Good

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

3 new filings were in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-05-05 10:02:25

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-04 16:39:32

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-04-30 14:24:38

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-16 18:00:28

Form ARS

Unknown Form Type

Filed on 2026-04-02 16:32:48

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-04-02 16:31:39

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-02 16:30:52

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 13:54:06

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-24 18:04:35

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-03-23 16:49:18

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 19:04:02

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-10 19:04:01

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$21.00

31.7%

Avg:

$15.83

-0.8%

Low:

$12.12

-24.0%

(% change is relative to the current stock price: $15.95)

Analyst Recommendations

Go to Analyst Tab

3.83

Good

22%

Strong Buy (4)

44%

Buy (8)

28%

Hold (5)

Sell (1)

Strong Sell (0)

About

Website
https://www.viatris.com/en
Address
1000 Mylan Boulevard, Canonsburg PENNSYLVANIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1792044

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. The company is headquartered in Canonsburg, Pennsylvania and currently employs 30,000 full-time employees. The firm's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. The company produces oral solid doses, injectables, and products with complex dosage forms.

IPO Date

1973-02-01

Industry

Pharmaceuticals

Total Employees

30,000

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Pharmaceuticals

GICS Sub

Pharmaceuticals

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

VTRS - Viatris Inc

51

$15.95

$0.43 (2.771%)

$15.83

-$0.13 (-0.784%)

2.57/5

Stock Unlock

Stock Profile

Score Card

Bad

Insider Transactions

Market News

Form SCHEDULE 13G/A

Filed on 2026-05-05 10:02:25

Form 8-K

Filed on 2026-05-04 16:39:32

Form SCHEDULE 13G

Filed on 2026-04-30 14:24:38

Form 4

Filed on 2026-04-16 18:00:28

Form ARS

Filed on 2026-04-02 16:32:48

Form DEFA14A

Filed on 2026-04-02 16:31:39

Form DEF 14A

Filed on 2026-04-02 16:30:52

Form SCHEDULE 13G/A

Filed on 2026-03-27 13:54:06

Form 4

Filed on 2026-03-24 18:04:35

Form 144

Filed on 2026-03-23 16:49:18

Form 4

Filed on 2026-03-10 19:04:02

Form 4

Filed on 2026-03-10 19:04:01

Financials

Price Targets

31.7%

-0.8%

-24.0%

Analyst Recommendations

About

Similar Stocks